Our library of drug research abstracts drawn from the medical literature is updated on a regular schedule, and you can be assured that new cleocin-t research articles will be listed here shortly after becoming available to us.
Related Sponsors
Medical research on cleocin-t
J Dermatolog Treat. 2002 Sep; 13(3): 107-10
Gans EH, Kligman AM
BACKGROUND: Benzoyl peroxide and clindamycin are the two most widely prescribed topical antimicrobials in the treatment of acne. AIM: To compare the antimicrobial efficacy, in vivo, of benzoyl peroxide and clindamycin against Propionibacterium acnes. METHODS: Two groups of 10 subjects each, with comparable mean P. acnes baseline counts of log 5.75 to 5.85, underwent twice daily application of benzoyl peroxide or clindamycin for 14 days. RESULTS: The results of quantitatively sampling P. acnes after 3, 7 and 14 days of treatment showed that Triaz 6% benzoyl peroxide special gel produced faster and significantly greater reductions in P. acnes than did the 1% clindamycin phosphate in Cleocin-T lotion (p < 0.01). These results were paralleled by the greater reductions produced by Triaz versus Cleocin (p < 0.05) in P. acnes fluorescence. CONCLUSION: Benzoyl peroxide formulations suppress the follicular population of P. acnes more rapidly and to a greater degree than topical antibiotics such as clindamycin.
Clindamycin phosphate 1% gel in acne vulgaris.
Adv Ther. 2001 Nov-Dec; 18(6): 244-52
Rizer RL, Sklar JL, Whiting D, Bucko A, Shavin J, Jarratt M
A 12-week study compared Clindagel, a unique water-based gel formulation of clindamycin phosphate 1%, administered once daily, and Cleocin T, a slightly different gel formulation indicated for twice-daily use, in the treatment of acne vulgaris. Clindagel was safe and effective and equivalent to Cleocin T gel, albeit with a better tolerability profile. Clindagel is a viable alternative to Cleocin T gel.
J Am Acad Dermatol. 1990 Mar; 22(3): 489-95
Schachner L, Pestana A, Kittles C
One hundred three patients with acne vulgaris were randomly designated to receive either a topical formulation of erythromycin plus zinc or a topical solution of 1% clindamycin phosphate (Cleocin-T). The patients treated themselves twice daily and were examined at 3, 6, 9, and 12 weeks after the start of therapy. By week 6 the overall severity grade was consistently lower and the percent reduction of severity, papules, pustules, and total comedones was higher in the erythromycin-zinc-treated group than in the clindamycin-treated group. In the 92 patients who completed this study (48 receiving erythromycin-zinc and 44 receiving clindamycin), no serious topical or systemic side effects were reported. Two patients, one from each treatment group, suffered mild irritation. One patient was withdrawn from the erythromycin-zinc-treated group. Results of patch tests were negative. The superiority of the erythromycin-zinc formulation may be due to the increased (4%) erythromycin concentration and/or the ability of 1.2% zinc acetate to enhance the product's activity.
Absorption kinetics of topical clindamycin preparations.
Biopharm Drug Dispos. 1989 Sep-Oct; 10(5): 505-12
Eller MG, Smith RB, Phillips JP
Systemic clindamycin absorption was examined in 12 male Caucasians without acne who received 1 ml of Cleocin-T and 1 ml of 1 per cent clindamycin HCl in Vehicle-N (Neutrogena) applied topically the face every 12 h for 4 days according to a crossover design. In a separate phase clindamycin phosphate was administered by an IV infusion of 300 mg over 10 min. Systemic absorption was much higher with clindamycin in Vehicle-N than with Cleocin-T. Absolute bioavailability calculated from cumulative urinary excretion and serum AUCs were in good agreement and averaged 1.7 per cent and 7.5 per cent for Cleocin-T and clindamycin in Vehicle-N, respectively. Peak serum concentrations ranged from less than 0.5 ng ml-1 to 6 ng ml-1 for Cleocin-T and from 4-20 ng ml-1 for clindamycin in Vehicle-N. Absorption profiles indicated zero order absorption with Cleocin-T. No appreciable systemic accumulation from the repeated topical applications was noted. Systemic exposure to clindamycin from these formulations is minimal.
A comparative study of benzoyl peroxide and clindamycin phosphate for treating acne vulgaris.
Br J Dermatol. 1988 Nov; 119(5): 615-22
Swinyer LJ, Baker MD, Swinyer TA, Mills OH
A water based 5% benzoyl peroxide gel (Benzac W5) was compared with topical 1% clindamycin phosphate solution (Cleocin T) in the treatment of acne vulgaris using a randomized, investigator blind study design. Lesion counts were significantly reduced in both treatment groups over the 12-week study period; however, the reduction of total lesions produced by benzoyl peroxide gel was significantly greater than that produced by clindamycin phosphate (P less than 0.05). Clindamycin phosphate had a milder effect on the skin surface in terms of peeling and drying than the benzoyl peroxide gel.
A comparison of Cleocin T Solution, Cleocin T Gel, and placebo in the treatment of acne vulgaris.
Cutis. 1988 Sep; 42(3): 245-7
Ellis CN, Gammon WR, Stone DZ, Heezen-Wehner JL
A twelve-week study in which investigators were blinded to the agents studied included 135 patients (aged twelve to thirty-five years) with moderately severe acne vulgaris. Patients were randomized into groups to compare the efficacy and local tolerance of 1 percent clindamycin phosphate gel, 1 percent clindamycin phosphate solution, and the gel vehicle which served as a placebo. One hundred and twenty-eight patients who completed at least six weeks of treatment were evaluated for efficacy of these agents. Both the solution and the gel were equivalent in reducing papule and pustule counts and results were superior to those produced by the placebo. All three treatments were tolerated well.
Cutis. 1985 Sep; 36(3): 265-8
Goltz RW, Coryell GM, Schnieders JR, Neidert GL
A randomized, investigator-blind study was conducted to compare the efficacy and skin tolerance of Cleocin T Topical 1 percent Solution and Cleocin T Topical 1 percent Lotion. Both treatments reduced acne lesion counts. More than 70 percent of the evaluable patients receiving each treatment reported that their acne improved by the end of the twelve-week study. Skin dryness was reported significantly more often by patients applying the solution than by those applying the lotion. This newly developed lotion formulation of topical clindamycin phosphate is equal in efficacy to, and appears to be less irritating than, Cleocin T Topical Solution.
Cutis. 1980 Oct; 26(4): 424-5, 429
Stoughton RB, Cornell RC, Gange RW, Walter JF
An eight week double-blind study comparing 1 percent clindamycin phosphate (Cleocin T) applied topically with tetracycline 500 mg a day taken orally was conducted in fifty subjects. Topically applied 1 percent clindamycin phosphate was found to be superior to oral tetracycline at six weeks as judged by patient evaluation and reduction of papules. There was a consistent trend favoring clindamycin phosphate at the other visits but the difference was not significant. The use of topically applied 1 percent clindamycin phosphate seems to be a logical alternative to the use of oral tetracycline.